Literature DB >> 2044183

Inhibition by dietary oltipraz of experimental intestinal carcinogenesis induced by azoxymethane in male F344 rats.

C V Rao1, K Tokomo, G Kelloff, B S Reddy.   

Abstract

Epidemiological studies suggest that consumption of cruciferous vegetables rich in dithiolethiones is associated with a reduction in the incidence of cancer in man. The effect of two dose levels of dietary oltipraz [5-(2-pyrazinyl)-4-methyl-1, 2- dithiole-3-thione], a substituted dithiolethione, on azoxymethane (AOM)-induced intestinal carcinogenesis and on serum levels was studied in male F344 rats. The maximum tolerated dose (MTD) of oltipraz was determined in male F344 rats and found to be 500 p.p.m. Oltipraz at levels of 200 p.p.m. (40% MTD) and 400 p.p.m. (80% MTD) diet was tested as inhibitor of intestinal carcinogenesis. At 5 weeks of age, animals were fed the modified AIN-76A (control) diet and experimental diets containing oltipraz. At 7 weeks of age, all animals except the vehicle-treated animals were administered s.c. injection of AOM (15 mg/kg body wt/week for 2 weeks). Animals intended for vehicle treatment were administered s.c. with an equal volume of normal saline. Fifty-two weeks later, all animals were killed and colon and small intestinal tumor incidences and multiplicity were compared among the dietary groups. The results indicate that feeding of 200 and 400 p.p.m. of oltipraz significantly inhibited the incidence of adenocarcinomas in colon and small intestine and multiplicity of colon adenomas and small intestinal adenocarcinomas. Animals fed 400 p.p.m. oltipraz showed increased levels of oltipraz in the serum as compared to those fed 200 p.p.m. oltipraz. The results of this study indicate that dietary oltipraz inhibits intestinal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2044183     DOI: 10.1093/carcin/12.6.1051

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

1.  Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz.

Authors:  P J O'Dwyer; C E Szarka; K S Yao; T C Halbherr; G R Pfeiffer; F Green; J M Gallo; J Brennan; H Frucht; E B Goosenberg; T C Hamilton; S Litwin; A M Balshem; P F Engstrom; M L Clapper
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

Review 2.  Targeting NRF2 signaling for cancer chemoprevention.

Authors:  Mi-Kyoung Kwak; Thomas W Kensler
Journal:  Toxicol Appl Pharmacol       Date:  2009-09-02       Impact factor: 4.219

3.  Synthesis and characterization of a novel iNOS/Akt inhibitor Se,Se'-1,4-phenylenebis(1,2-ethanediyl)bisisoselenourea (PBISe)--against colon cancer.

Authors:  Dhimant Desai; SubbaRao V Madhunapantula; Krishnegowda Gowdahalli; Arati Sharma; Raghavendragowda Chandagaludoreswamy; Karam El-Bayoumy; Gavin P Robertson; Shantu Amin
Journal:  Bioorg Med Chem Lett       Date:  2009-09-22       Impact factor: 2.823

4.  Interactions of the major metabolite of the cancer chemopreventive drug oltipraz with cytochrome c: a novel pathway for cancer chemoprevention.

Authors:  Murugesan Velayutham; Rajendra B Muthukumaran; Joe Z Sostaric; John McCraken; James C Fishbein; Jay L Zweier
Journal:  Free Radic Biol Med       Date:  2007-07-06       Impact factor: 7.376

5.  Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication.

Authors:  H J Prochaska; Y Yeh; P Baron; B Polsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

Review 6.  Dithiolethiones for cancer chemoprevention: where do we stand?

Authors:  Yuesheng Zhang; Rex Munday
Journal:  Mol Cancer Ther       Date:  2008-11       Impact factor: 6.261

Review 7.  Perspectives in cancer chemoprevention.

Authors:  G D Stoner; M A Morse; G J Kelloff
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.